Mounjaro is a diabetes drug made by Eli Lilly and Company. More recently, Mounjaro (and similar drugs such as Ozempic and Wegovy) have become widely used for weight loss and weight management in obese patients. However, new evidence suggests that using higher doses of Mounjaro for weight loss may cause serious health problems involving the gallbladder and gastrointestinal system. Mounjaro use has been linked to gallbladder disease, gallstones, gastroparesis (gastric paralysis), and other stomach problems.
Eli Lilly was clearly aware of these dangerous risks associated with Mounjaro but failed to warn doctors and patients. Individuals who used Mounjaro and suffered some injuries are now filing Mounjaro product liability lawsuits. The national mass tort attorneys at Miller & Zois are currently investigating new Mounjaro injury cases. If you are taking Mounjaro for weight loss and have gallbladder or gastrointestinal issues, please contact us for a free case evaluation. Please call us at 800-553-8082.
Mounjaro is the brand name of Tirzepatide. Mounjaro is a drug designed to treat type 2 diabetes. Mounjaro is administered weekly by subcutaneous injection. It belongs to a family of anti-diabetic drugs that work by stimulating the production and release of certain hormones in the gut, triggering the body to release insulin.
Mounajro was developed and patented by Eli Lilly and Company, one of the world’s largest pharmaceutical companies. Mounjaro is a relatively new drug. It was just approved for medical use in the United States in May 2022. When it was approved by the FDA, Mounjaro was considered the first of its kind.
Although Mounjaro was only approved as a diabetes drug, it almost immediately became popular with physicians in the treatment and management of weight loss in obese patients. This “off-label” weight loss use is also popular among similar diabetes drugs such as Ozempic and Wegovy.
Mounjaro may cause gastrointestinal and gallbladder problems
A growing body of research shows that using Mounjaro may cause very serious health problems involving the gastrointestinal system and gallbladder. The risk of these problems is particularly high when using Mounjaro for weight loss because higher doses are required.
Mounjaro is associated with the following health conditions, all of which can be serious or even life-threatening.
Gastroparesis: Also known as “gastric paralysis,” this is a condition in which the stomach muscles stop moving normally. People with gastroparesis experience slowed or complete gastric motility failure, resulting in improper gastric emptying. This can be a very painful and potentially serious condition that can lead to other internal complications.
Gastroenteritis This is infection and inflammation of the digestive system that can cause stomach cramps, diarrhea, and vomiting. The most worrisome complication of gastroenteritis is dehydration.
Gallbladder disease: Mounjaro and similar drugs have been linked to gallbladder disease. This involves chronic inflammation of the gallbladder and the development of gallstones and other problems. It can be very painful and in some cases requires surgery to remove the gallbladder.
Currently, an increasing number of Mounjaro product liability lawsuits are being filed across the country. These lawsuits were filed by individuals who used Mounjaro to lose weight and subsequently suffered the gastrointestinal or gallbladder injuries described above.
The Mounjaro lawsuit centered on failure to warn. They claim Eli Lilly knew (or should have known) that regular use of higher doses of Mounjar could cause health problems such as gastroparesis or gallbladder disease. Despite knowing this, the lawsuit alleges that Eli Lilly failed to include any warnings about these specific risks on Mounjaro’s drug labels. As a result, doctors and patients were never made aware of the potential risks associated with Mounjaro.
Mounjaro class action lawsuit
As of October 2023, there has been no Mounjaro “class action lawsuit” or MDL. However, the Mounjaro lawsuit may be consolidated into a class action MDL at some point in the near future. The Ozempic lawsuit (a drug very similar to Mounjaro) was just recently consolidated into a new class action MDL. The charges in the Ozempic case are very similar to those in the Mounjaro case.
If a new Mounjaro class action MDL is created, all Mounjaro lawsuits pending in federal courts across the country will be consolidated and heard by a single judge. The merged cases will go through the discovery phase together. At the end of the discovery phase, a small number of representative cases from the group are selected for trial. These are called bellwether trials. The results of these tests should give parties an idea of what would happen if all cases went to trial so that they can negotiate global settlements.
Estimated settlement amount in Mounjaro lawsuit
At this early stage, it is almost impossible to truly accurately estimate the settlement value of the Mounjaro lawsuit. The biggest unknown right now is whether the scientific evidence behind these cases will hold up in court. That’s always a big issue with pharmaceutical cases like this.
However, if we make some assumptions about how things will play out, we can make an educated guess about the settlement value of these cases. Based on these important assumptions, our attorneys believe that a successful settlement in the Mounjaro litigation is likely to range from $150,000 to $300,000. This is lower than our estimate of the value of the Ozempic lawsuit, primarily because Mounjaro has been on the market for a shorter period of time. This means that the Mounjaro plaintiffs have less exposure to the drug than the Ozempic plaintiffs, which will make the Mounjaro case somewhat weaker.
Hire an Attorney for Your Mounjaro Lawsuit
If you believe you have been harmed by Mounjaro and want to consider filing a Mounjaro lawsuit, the first thing you need to do is hire an attorney. Please contact our attorneys today: 800-553-8082 Or contact us online.